Taken together, these results suggested that in addition to suppress growth of cancer cells, BET inhibitors may also enhance the immunity of AML patients by suppressing the expression of PD-L1 on AML cells and the expression of PD-1 and Tim-3 on exhausted T cells. The gene discussed is HAVCR2; the disease is cancer.